Innovation and industry-academia interactions: Where conflicts arise and measures to avoid them
P. Roy Vagelos, MD
Chairman, Regeneron Pharmaceuticals, Inc.; Chairman, Theravance, Inc.; Former CEO, Merck & Co., Inc.
Correspondence: P. Roy Vagelos, MD, 1 Crossroads Drive, Bedminster, NJ 07921; firstname.lastname@example.org
Dr. Vagelos reported that he has no financial interests, relationships, or affiliations that pose a potential conflict of interest with this article.
Every phase of the development of biopharmaceuticals and medical devices has the potential for conflict of interest, but adherence to established rules and practices throughout product development can eliminate the possibility of conflicts. Adherence to good practices should continue through the postmarketing period, with swift reporting and vigorous investigation of any safety concerns. Although some academic medical centers are restricting interactions between their faculty and industry to prevent possible conflicts in physician education about new products, industry and academia should look for new ways to come together in mutually agreed forums that focus on educating clinicians about new products in an efficient, transparent way.